| [1] | Tomicic MT, Christmann M, Kaina B.Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival[J].Cancer Res,2005,65(19):8920-8926. |
| [2] | Armstrong DK, Spriggs D, Levin J, et al.Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer:an integrated analysis[J].Oncologist,2005,10(9):686-694. |
| [3] | Gordon AN, Fleagle JT, Guthrie D,et al.Recurrent epithelial ovarian carcinoma:a randomized phaseⅢ study of pegylated liposomal doxorubicin versus topotecan[J].J Clin Oncol,2001,19(14):3312-3322. |
| [4] | Vandenput I, Amant F, Neven P, et al.Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer[J].Int J Gynecol Cancer,2007,17(1):83-87. |
| [5] | Abushahin F, Singh DK, Lurain JR,et al.Weekly topotecan for recurrent platinum resistant ovarian cancer[J].Gynecol Oncol,2008,108(1):53-57. |
| [6] | Herzog TJ, Sill MW, Walker JL, et al.A phase Ⅱ study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer:a gynecologic oncology group study (GOG 146Q)[J].Gynecol Oncol,2011,120(3):454-458. |
| [7] | Sehouli J, Stengel D, Harter P,et al.Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer:a randomized multicenter phase Ⅱ trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group[J].J Clin Oncol,2011,29(2):242-248. |
| [8] | 刘勇,席青松,赵荆,等.两种方案治疗难治/耐药型小细胞肺癌比较[J].药物与临床,2011,30(5):598-601. |